T细胞双特异性抗体用于淋巴结阳性乳腺癌:MHC I类分子缺失变异的新治疗途径
该研究通过功能性流式细胞术分析早期乳腺癌原发灶与转移性腋窝淋巴结在化疗前后对桥接CD3ε与HER2或CEACAM5的T细胞双特异性抗体的免疫动态,并评估HLA I类分子缺失。结果显示HLA杂合性缺失存在于早期乳腺癌并与调节性T细胞等免疫抑制因素相关,而T细胞双特异性抗体可绕过MHC I类分子缺失、部分恢复转移淋巴结中的T细胞功能。
要点
- 早期乳腺癌中可观察到HLA杂合性缺失,且与调节性T细胞及TIM-3表达相关。
- 桥接CD3ε与HER2或CEACAM5的T细胞双特异性抗体可绕过MHC I类分子缺失。
- T细胞双特异性抗体可部分恢复转移性淋巴结中的T细胞功能。
核心结论
- T细胞双特异性抗体应在乳腺癌中开发,以规避低MHC/肽复合物。
研究设计与样本
- 研究通过功能性流式细胞术分析早期乳腺癌原发灶和转移性腋窝淋巴结在化疗前后暴露于桥接CD3ε与HER2或CEACAM5的T细胞双特异性抗体的免疫动态。
主要发现
- 在早期乳腺癌中观察到HLA杂合性缺失,呈克隆和亚克隆水平,并与调节性T细胞及T细胞免疫球蛋白和黏蛋白结构域3表达相关,抑制了新辅助化疗的免疫刺激效应。
- 桥接CD3ε与HER2或CEACAM5的T细胞双特异性抗体可绕过主要组织相容性复合体I类分子缺失,部分恢复转移性淋巴结中的T细胞功能。
关键数值与推荐
- 分析了100例原发乳腺癌、64例周围「健康组织」和24例转移性淋巴结的相关参数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancer (BC). Nonetheless, neoepitope load and TILs cytolytic activity are modest in BC, compromising the efficacy of immune-activating antibodies, which do not yet compete against immunogenic chemotherapy. PATIENTS AND METHODS: We analyzed by functional flow cytometry the immune dynamics of primary and metastatic axillary nodes [metastatic lymph nodes (mLN)] in early BC (EBC) after exposure to T-cell bispecific antibodies (TCB) bridging CD3ε and human epidermal growth factor receptor 2 (HER2) or Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), before and after chemotherapy. Human leukocyte antigen (HLA) class I loss was assessed by whole exome sequencing and immunohistochemistry. One hundred primary BC, 64 surrounding 'healthy tissue' and 24 mLN-related parameters were analyzed. RESULTS: HLA loss of heterozygosity was observed in EBC, at a clonal and subclonal level and was associated with regulatory T cells and T-cell immunoglobulin and mucin-domain-3 expression restraining the immuno-stimulatory effects of neoadjuvant chemotherapy. TCB bridging CD3ε and HER2 or CEACAM5 could bypass major histocompatibility complex (MHC) class I loss, partially rescuing T-cell functions in mLN. CONCLUSION: TCB should be developed in BC to circumvent low MHC/peptide complexes.
引用
- Messaoudene M, Mourikis TP, Michels J, et al. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Ann Oncol. 2019. PMID: 30924846. doi:10.1093/annonc/mdz112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。